Ministry of Chemicals and Fertilizers : press release · 27 March 2026 · pibtracker filter

Production Linked Incentive Scheme for Pharmaceuticals

PRID2246068 MinistryMinistry of Chemicals and Fertilizers : Released27 March 2026 Reading6 min

Posted On: 27 MAR 2026 4:26PM by PIB Delhi The status of implementation of Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India (commonly known as “PLI scheme for Bulk Drugs”) is as follows: i. Till December 2025, investment of ₹4,814 crore has been made against an investment commitment of ₹4,329.95 crore in greenfield projects. ii. Total capacity amounting to 91,077 metric tonnes per annum is committed for 33 subscribed products as against originally envisaged capacity of 82,270 metric tonnes per annum for 41 products identified (List of 41 products is placed at Annexure). Further, manufacturing capacity of 56,800 metric tonnes per annum has been created for 28 critical KSMs, DIs, and APIs till December, 2025. The scheme has resulted in cumulative sales of ₹2,720 crore, including exports of ₹527.96 crores. Department of Pharmaceuticals is implementing a scheme, namely the scheme for Promotion of Bulk Drug Parks, with a budgetary outlay of ₹3,000 crore, under which three bulk drug parks have been approved and are at various stages of development in the States of Andhra Pradesh, Gujarat and Himachal Pradesh, through their respective State implementing agencies. The total project cost of these parks is over ₹6,306.68 crore, with Central assistance to the tune of ₹1,000 crore each for creation of common infrastructure facilities. These parks envisage land and utilities such as power, water, effluent treatment plant, steam, solid waste management and warehouse facilities at a subsidised rate to bulk drug or API manufacturers for units set up in the park. The State implementing agencies of the States concerned have also offered fiscal incentives in the form of capital subsidy on fixed capital investment, interest subsidy, State Goods and Services Tax reimbursement, exemption of stamp duty and registration charges, etc. Further, the scheme provides for applicants for allotment of land in the parks to set up units for manufacturing products prioritised in the PLI Scheme for Bulk Drugs to have priority in land allotment. The Production Linked Incentive (PLI) scheme aims to enhance India’s manufacturing capabilities by increasing investment and production in the pharmaceuticals sector and contributing to product diversification to high-value goods in the pharmaceutical sector and incentivises production of high-value medicines such as biopharmaceuticals, complex generic drugs, patented drugs or drugs nearing patent expiry, auto-immune drugs, anti-cancer drugs, etc. The total cumulative investment attracted and the number of direct and indirect employment opportunities generated in the pharmaceutical sector since the launch of the said schemes, year- wise is given below: Cumulative investment (in crore ₹) till Employment (Nos.) opportunities generated till March 2023 March 2024 March 2025 December 2025 March 2023 March 2024 March 2025 December 2025 PLI Scheme for Bulk Drugs 2,374.93 3,721.44 4,554.25 4,814.10 2,163 3,538 4,490 4,896 PLI Scheme for Pharmaceuticals 20,647 29,268 37,306.65 42,694.89 46,357 70,362 93,532 1,13,300 Annexure S. No. Name of Products covered under PLI Scheme for Bulk Drugs Penicillin G 7-ACA Clavulanic Acid Erythromycin Thiocyanate (TIOC) Betamethasone Dexamethasone Prednisolone Rifampicin Clindamycin Base Streptomycin Tetracycline Neomycin Gentamycin Para Amino Phenol 1,1 Cyclohexane Diacetic Acid (CDA) Dicyandiamide (DCDA) 2-Methyl-5-Nitro-Imidazole (2-MNI) Meropenem Atorvastatin Olmesartan Valsartan Losartan Levofloxacin Sulfadiazine Ofloxacin Norfloxacin Artesunate Telmisartan Aspirin Levetiracetam Carbidopa Ritonavir Lopinavir Acyclovir Carbamazepine Oxcarbazepine Vitamin B6 Levodopa Vitamin B1 Diclofenac Sodium Ciprofloxacin This information was given by Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in a written reply in the Lok Sabha today. ***** PC/PM (Release ID: 2246068) Visitor Counter : 706 Read this release in: Urdu , हिन्दी Ministry of Chemicals and Fertilizers : Department of Pharmaceuticals Production Linked Incentive Scheme for Pharmaceuticals Posted On: 27 MAR 2026 4:26PM by PIB Delhi The status of implementation of Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India (commonly known as “PLI scheme for Bulk Drugs”) is as follows: i. Till December 2025, investment of ₹4,814 crore has been made against an investment commitment of ₹4,329.95 crore in greenfield projects. ii. Total capacity amounting to 91,077 metric tonnes per annum is committed for 33 subscribed products as against originally envisaged capacity of 82,270 metric tonnes per annum for 41 products identified (List of 41 products is placed at Annexure). Further, manufacturing capacity of 56,800 metric tonnes per annum has been created for 28 critical KSMs, DIs, and APIs till December, 2025. The scheme has resulted in cumulative sales of ₹2,720 crore, including exports of ₹527.96 crores. Department of Pharmaceuticals is implementing a scheme, namely the scheme for Promotion of Bulk Drug Parks, with a budgetary outlay of ₹3,000 crore, under which three bulk drug parks have been approved and are at various stages of development in the States of Andhra Pradesh, Gujarat and Himachal Pradesh, through their respective State implementing agencies. The total project cost of these parks is over ₹6,306.68 crore, with Central assistance to the tune of ₹1,000 crore each for creation of common infrastructure facilities. These parks envisage land and utilities such as power, water, effluent treatment plant, steam, solid waste management and warehouse facilities at a subsidised rate to bulk drug or API manufacturers for units set up in the park. The State implementing agencies of the States concerned have also offered fiscal incentives in the form of capital subsidy on fixed capital investment, interest subsidy, State Goods and Services Tax reimbursement, exemption of stamp duty and registration charges, etc. Further, the scheme provides for applicants for allotment of land in the parks to set up units for manufacturing products prioritised in the PLI Scheme for Bulk Drugs to have priority in land allotment. The Production Linked Incentive (PLI) scheme aims to enhance India’s manufacturing capabilities by increasing investment and production in the pharmaceuticals sector and contributing to product diversification to high-value goods in the pharmaceutical sector and incentivises production of high-value medicines such as biopharmaceuticals, complex generic drugs, patented drugs or drugs nearing patent expiry, auto-immune drugs, anti-cancer drugs, etc. The total cumulative investment attracted and the number of direct and indirect employment opportunities generated in the pharmaceutical sector since the launch of the said schemes, year- wise is given below: Cumulative investment (in crore ₹) till Employment (Nos.) opportunities generated till March 2023 March 2024 March 2025 December 2025 March 2023 March 2024 March 2025 December 2025 PLI Scheme for Bulk Drugs 2,374.93 3,721.44 4,554.25 4,814.10 2,163 3,538 4,490 4,896 PLI Scheme for Pharmaceuticals 20,647 29,268 37,306.65 42,694.89 46,357 70,362 93,532 1,13,300 Annexure S. No. Name of Products covered under PLI Scheme for Bulk Drugs Penicillin G 7-ACA Clavulanic Acid Erythromycin Thiocyanate (TIOC) Betamethasone Dexamethasone Prednisolone Rifampicin Clindamycin Base Streptomycin Tetracycline Neomycin Gentamycin Para Amino Phenol 1,1 Cyclohexane Diacetic Acid (CDA) Dicyandiamide (DCDA) 2-Methyl-5-Nitro-Imidazole (2-MNI) Meropenem Atorvastatin Olmesartan Valsartan Losartan Levofloxacin Sulfadiazine Ofloxacin Norfloxacin Artesunate Telmisartan Aspirin Levetiracetam Carbidopa Ritonavir Lopinavir Acyclovir Carbamazepine Oxcarbazepine Vitamin B6 Levodopa Vitamin B1 Diclofenac Sodium Ciprofloxacin This information was given by Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in a written reply in the Lok Sabha today. ***** PC/PM (Release ID: 2246068) The status of implementation of Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India (commonly known as “PLI scheme for Bulk Drugs”) is as follows: i. Till December 2025, investment of ₹4,814 crore has been made against an investment commitment of ₹4,329.95 crore in greenfield projects. <span style="f

Original PIB release
pib.gov.in · PRID 2246068

Open on PIB ↗

Production Linked Incentive Scheme for Pharmaceuticals

More from this day